|
 |
|
|||||||
|
|||||||||
Copyright ©ERS Journals Ltd 2008
Bronchodilator responsiveness in patients with COPD
1 David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, 2 St Elizabeth’s Medical Center, Boston, MA, and 4 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 3 University Hospitals, Leuven, Belgium, 5 Boehringer Ingelheim GmbH, Ingelheim, Germany.
CORRESPONDENCE: D. P. Tashkin, David Geffen School of Medicine, UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90024, USA. Fax: 1 3102065088. E-mail: DTashkin{at}mednet.ucla.edu
Keywords: Bronchodilator, chronic obstructive pulmonary disease, reversibility, spirometry, tiotropium
Received: October 2, 2007
Accepted January 17, 2008
The degree of acute improvement in spirometric indices after bronchodilator inhalation varies among chronic obstructive pulmonary disease (COPD) patients, and depends upon the type and dose of bronchodilator and the timing of administration.
Acute bronchodilator responsiveness at baseline was examined in a large cohort of patients with moderate-to-very-severe COPD participating in the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial, a 4-yr randomised double-blind trial evaluating the efficacy of 18 µg tiotropium daily in reducing the rate of decline in lung function. After wash-out of respiratory medications, patients received 80 µg ipratropium followed by 400 µg salbutamol. Spirometry was performed before and 90 min following ipratropium administration. The criteria used for forced expiratory volume in one second (FEV1) responsiveness were:
Of the patients, 5,756 had data meeting the criteria for analysis (age 64.5 yrs; 75% male; baseline FEV1 1.10 L (39.3% predicted) and forced vital capacity (FVC) 2.63 L). Compared with baseline, mean improvements were 229 mL in FEV1 and 407 mL in FVC. Of these patients, 53.9% had
The majority of patients with moderate-to-very-severe chronic obstructive pulmonary disease demonstrate meaningful increases in lung function following administration of inhaled anticholinergic plus sympathomimetic bronchodilators.
12% increase over baseline and 200 mL; 15% increase over baseline; and 10% absolute increase in the percentage predicted value. 12% and 200 mL improvement in FEV1, 65.6% had 15% improvement in FEV1, and 38.6% had 10% absolute increase in FEV1 % pred.
This article has been cited by other articles:
|
|
 |
|
  D. S. Postma and P. Calverley Inhaled corticosteroids in COPD: a case in favour Eur. Respir. J., July 1, 2009; 34(1): 10 - 12. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Dellaca, P. P. Pompilio, P. P. Walker, N. Duffy, A. Pedotti, and P. M. A. Calverley Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD Eur. Respir. J., June 1, 2009; 33(6): 1329 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Keaney, A. Kay, and I. Taylor Guidelines and the Diagnosis of COPD Am. J. Respir. Crit. Care Med., April 15, 2009; 179(8): 734 - 734. [Full Text] [PDF]
|
|
|
|
|
|
J. D Maclay, R. A Rabinovich, and W. MacNee Update in Chronic Obstructive Pulmonary Disease 2008 Am. J. Respir. Crit. Care Med., April 1, 2009; 179(7): 533 - 541. [Full Text] [PDF]
|
|
|
|
 |
|
 M Hasegawa, H Makita, Y Nasuhara, N Odajima, K Nagai, Y Ito, T Betsuyaku, and M Nishimura Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD Thorax, April 1, 2009; 64(4): 332 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D'Urzo MD MSc Spirometry in primary care practices Can. Med. Assoc. J., February 17, 2009; 180(4): 429 - 430. [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, S. Menjoge, M. Decramer, and the UPLIFT Study Investigators A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease N. Engl. J. Med., October 9, 2008; 359(15): 1543 - 1554. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |